ArticlePloS one2026
Spatiotemporal patterns of prevalence and mortality from respiratory infections and tuberculosis across Japan and its prefectures.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory infections and tuberculosis (RIT) remain major contributors to global morbidity and mortality. In rapidly ageing societies, demographic shifts may decouple disease occurrence from fatal outcomes. Japan offers a representative setting to examine long-term spatiotemporal patterns of RIT burden in an advanced ageing context.
methodsA population-based spatiotemporal analysis of Japan from 2010 to 2023 was conducted using standardized national and prefectural estimates. Annual RIT prevalence and deaths were examined by sex and age group. Long-term trends were quantified using estimated annual percentage change (EAPC) from log-linear models of rates, and changes in the etiological composition of RIT mortality were assessed by age and sex.
resultsNational RIT prevalence fell from 31.40 million cases in 2010 to 27.52 million in 2023, and the prevalence rate decreased from 24,536.02 to 22,070.66 per 100,000 (EAPC -1.11). In 2023, prevalent cases were similar between females (13.95 million) and males (13.57 million). Adults aged 75 years and older increased from 2.47 million prevalent cases in 2010 to 3.28 million in 2023 despite declining rates. Total RIT deaths decreased from 104,048 in 2010-98,091 in 2023, while the death rate changed from 81.31 to 78.68 per 100,000 (EAPC 0.83). Mortality remained higher in males than females, with 61,683 versus 36,407 deaths in 2023, and was concentrated in adults aged 75 years and older (87,545 deaths), although their death rate declined from 629.40 to 429.91 per 100,000. Across prefectures, prevalence rates declined universally (-8.47% to -56.30%), whereas deaths increased in most prefectures (-10.74% to 153.64%), with the largest rises observed in Saitama (153.64%), Chiba (130.41%), and Osaka (63.79%). Etiology-specific patterns shifted, with Streptococcus pneumoniae declining from 28.9% to 20.4% of deaths, while Staphylococcus aureus rose from 12.2% to 19.0% and Legionella spp. from 8.6% to 11.5%, most notably among adults aged 75 years and older.
conclusionsIn ageing settings exemplified by Japan, declining RIT prevalence can coexist with persistent, older-adult-concentrated mortality, subnational inequality, and an evolving etiological profile. Age-focused care, prefecture-tailored prevention, and etiology-aware management may reduce avoidable deaths and geographic disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.